CoChat

Aetiology of type 2 diabetes in people with a 'normal’ body mass index: testing the personal fat threshold hypothesis

Open access

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Weight loss in overweight or obese individuals with Type 2 diabetes (T2D) can normalize hepatic fat metabolism, decrease fatty acid oversupply to β cells and restore normoglycaemia. One in six people has BMI <27 kg/m2 at diagnosis, and their T2D is assumed to have different aetiology. The Personal Fat Threshold hypothesis postulated differing individual thresholds for lipid overspill and adverse effects on β-cell function. To test this hypothesis, people with Type 2 diabetes and body mass index <27kg/m2 (n = 20) underwent repeated 5% weight loss cycles. Metabolic assessments were carried out at stable weight after each cycle and after 12 months. To determine how closely metabolic features returned to normal, 20 matched normoglycemic controls were studied once. Between baseline and 12 months: BMI fell (mean ± SD), 24.8 ± 0.4 to 22.5 ± 0.4 kg/m2 (P<0.0001) (controls: 21.5 ± 0.5); total body fat, 32.1 ± 1.5 to 27.6 ± 1.8% (P<0.0001) (24.6 ± 1.5). Liver fat content and fat export fell to normal as did fasting plasma insulin. Post-meal insulin secretion increased but remained subnormal. Sustained diabetes remission (HbA1c < 48 mmol/mol off all glucose-lowering agents) was achieved by 70% (14/20) by initial weight loss of 6.5 (5.5–10.2)%. Correction of concealed excess intra-hepatic fat reduced hepatic fat export, with recovery of β-cell function, glycaemic improvement in all and return to a non-diabetic metabolic state in the majority of this group with BMI <27 kg/m2 as previously demonstrated for overweight or obese groups. The data confirm the Personal Fat Threshold hypothesis: aetiology of Type 2 diabetes does not depend on BMI. This pathophysiological insight has major implications for management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/cs20230586

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Time course of change in major clinical parameters after each cycle of weight loss and at 12 months Changes in mean (+SEM) BMI, weight, % body fat, waist circumference, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) in the T2D group during the intervention at each time point. Numbers of participants and level of statistical significance vs. baseline are shown below each time point. The dotted line shows the mean control values for each parameter.
Figure 1 Time course of change in major clinical parameters after each cycle of weight loss and at 12 months Changes in mean (+SEM) BMI, weight, % body fat, waist circumference, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) in the T2D group during the intervention at each time point. Numbers of participants and level of statistical significance vs. baseline are shown below each time point. The dotted line shows the mean control values for each parameter.CC BY · PubMed Central
Figure 2 Major pathophysiological parameters at baseline, at the Clinical End Point of HbA1c <48mmol/mol (CEP) and at 12 months Median (IQR) liver fat, very low-density lipoprotein-1 (VLDL) triglyceride, plasma triglycerides with palmitic acid content reflecting rate of de novo lipogenesis, total plasma triglyceride, and Disposition Index at baseline, the co-primary end points of CEP (clinical end point; HbA1c <48 mmol/mol) and at 12 months in the T2D group. Numbers of participants and level of statistical significance vs. baseline are shown below CEP and 12 months. Non-diabetic control data are also shown with the level of significance vs. T2D at 12 months below ‘Control’.
Figure 2 Major pathophysiological parameters at baseline, at the Clinical End Point of HbA1c <48mmol/mol (CEP) and at 12 months Median (IQR) liver fat, very low-density lipoprotein-1 (VLDL) triglyceride, plasma triglycerides with palmitic acid content reflecting rate of de novo lipogenesis, total plasma triglyceride, and Disposition Index at baseline, the co-primary end points of CEP (clinical end point; HbA1c <48 mmol/mol) and at 12 months in the T2D group. Numbers of participants and level of statistical significance vs. baseline are shown below CEP and 12 months. Non-diabetic control data are also shown with the level of significance vs. T2D at 12 months below ‘Control’.CC BY · PubMed Central
Figure 3 Time course of change in glycaemic measures after each cycle of weight loss and at 12 months Change in mean (+SEM) HbA1c and fasting plasma glucose values in the T2D group during weight stability following each weight loss cycle and also after longer term follow up at 12 months. Numbers of participants and significance level versus baseline are shown below each time point.
Figure 3 Time course of change in glycaemic measures after each cycle of weight loss and at 12 months Change in mean (+SEM) HbA1c and fasting plasma glucose values in the T2D group during weight stability following each weight loss cycle and also after longer term follow up at 12 months. Numbers of participants and significance level versus baseline are shown below each time point.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 1

  1. White, 2013, Expression of mesenchymal and α-cell phenotypic markers in islet β-cells in recently diagnosed diabetes, Diabetes Care., 36, 3818, 10.2337/dc13-0705 · DOI · Paper page

Cited by

See all 77

Metadata

Authors
Taylor, R., Barnes, A. C., Hollingsworth, K. G., Irvine, K. M., Solovyova, A. S., Clark, L., Kelly, T., Martin-Ruiz, C., Romeres, D., Koulman, A., Meek, C. M., Jenkins, B., Cobelli, C., & Holman, R. R.
Affiliations
  • Newcastle University (GB)
  • University of Virginia (US)
  • University of Cambridge (GB)
  • 5Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Box 289, Cambridge Biomedical Campus, Cambridge, U.K.
  • University of Padua (IT)
  • University of Oxford (GB)
Corresponding author
Taylor, Roy
Venue
Clinical Science
Published
2023-08
Volume
137
Issue
16
Pages
1333-1346
ISSN
  • 0143-5221 (ISSN-L)
  • 1470-8736
OpenAlex
W4385969638
Cited by
71
References
56
Citations by year
2026: 16 · 2025: 24 · 2024: 31
FWCI
14.57
Type
journal article
Language
en
Open access
Locations
  • Clinical Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
Diabetes UK (17/0005645)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 2 diabetes, normal body mass index, weight loss, diabetes remission, liver fat, beta-cell function, insulin secretion, total body fat
MeSH terms
Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Body Mass Index, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aetiology of type 2 diabetes in people with a 'normal’ body mass index: testing the personal fat threshold hypothesis. https://app.cochat.ai/papers/10.1042/cs20230586
The paper
Taylor, R., Barnes, A. C., Hollingsworth, K. G., Irvine, K. M., Solovyova, A. S., Clark, L., Kelly, T., Martin-Ruiz, C., Romeres, D., Koulman, A., Meek, C. M., Jenkins, B., Cobelli, C., & Holman, R. R. (2023). Aetiology of type 2 diabetes in people with a 'normal’ body mass index: testing the personal fat threshold hypothesis. Clinical Science. https://doi.org/10.1042/cs20230586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.